Blog

Precision Medicine in the Pediatric Oncology Clinic: From Feasibility to Clinical Impact


VIEW THE PRESENTATION

Speaker:
Katherine Janeway
, MD, MSc
Associate Professor of Pediatrics
Harvard Medical School Director Clinical Genomics,Dana-Farber Cancer Institute
Senior Physician and Director Solid Tumor Service, Pediatric Oncology
Dana-Farber/Boston Children’s Cancer and Blood Disorders Center

Dr. Janeway is Associate Professor of Pediatrics at Harvard Medical School, and is the Director of Clinical Genomics and of the Pediatric Solid Tumor Program at Dana Farber Cancer Institute. Her research focus is applying cancer genomics to the pediatric oncology clinic and identifying central oncogenic mechanisms, novel drug targets and new therapeutics for sarcomas, malignancies in particular need of scientific and clinical advances. As Vice Chair of the Children’s Oncology Group Bone Tumor Committee, Dr. Janeway helps set priorities for clinical investigation and guides protocol development for collaborative trials in Ewing sarcoma and osteosarcoma. She sits on national committees charged with bringing the power of genomic characterization to patient care, e.g., she co-chairs the target and agent prioritization committee for the National Cancer Institute Pediatric MATCH study. Dr. Janeway received her MD from Harvard Medical School in 2000 and a Master of Medical Science from Harvard Medical School in 2008. She completed her residency in pediatrics at Boston Children’s Hospital where she later served as chief resident. Dr. Janeway then completed her fellowship in pediatric hematology-oncology at Dana-Farber Cancer Institute/Boston Children’s Hospital where she was also chief fellow before joining the staff in 2007.

Comments are closed.